PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.7, 2013-11, pp. : 927-932

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Moxifloxacin monotherapy on par with combination therapy in CAP

Inpharma, Vol. 1, Iss. 1539, 2006-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection

By Stout Jason E

Expert Opinion on Drug Safety, Vol. 3, Iss. 3, 2004-05 ,pp. : 187-198

Informa Healthcare

Access to resources Recommend Favorite

Immunosuppressants/isoniazid/pyrazinamide: Tuberculosis, hyperuricaemia and hepatotoxicity in an elderly patient: case report

Reactions Weekly, Vol. 1, Iss. 1409, 2012-01 ,pp. : 27-28

Adis International

Access to resources Recommend Favorite

Moxifloxacin

By Barman Balfour J.A. Wiseman L.R.

Drugs, Vol. 57, Iss. 3, 1999-03 ,pp. : 363-373

Adis International

Access to resources Recommend Favorite

Moxifloxacin moves in on standard therapy for complicated infections

Inpharma, Vol. 1, Iss. 1472, 2005-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite